Get started
Author

Zhewen Ren

Observed name: Ren, Zhewen
ORCID: 0009-0008-0065-4529
Observed ORCID: 0009-0008-0065-4529
OpenAlex ID: A5004425979
Relationship between NAFLD and coronary artery disease: A Mendelian randomization study
2022 · Zhewen Ren, Pomme I. H. G. Simons, et al. · Hepatology · 121
PDF
Cardiovascular Implications of Metabolic Dysfunction-Associated Fatty Liver Disease
2023 · Zhewen Ren, Anke Wesselius, et al. · Endocrinology and Metabolism Clinics of North America · 16
PDF
Traditional lifestyle factors partly mediate the association of socioeconomic position with intrahepatic lipid content: The Maastricht study
2023 · Zhewen Ren, Hans Bosma, et al. · JHEP Reports · 13
PDF
Plasma metabolomic profiling of dietary patterns associated with glucose metabolism status: The Maastricht Study
2022 · Evan Yi-Wen Yu, Zhewen Ren, et al. · BMC Medicine · 13
PDF
Efficacy of three modern anti-diabetic drugs on survival outcomes of lung cancer patients with type 2 diabetes in China
2025 · Zijia Chen, Ziyi Sun, et al. · Frontiers in Oncology · 7
PDF
Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization
2023 · Sontoria D. King, Swathi Veliginti, et al. · Cancer Epidemiology Biomarkers & Prevention · 7
Relationship between educational attainment and non-alcoholic fatty liver disease: A two-sample Mendelian randomization study
2023 · Zhewen Ren, Anke Wesselius, et al. · Digestive and Liver Disease · 5
PDF
Supplementary Table S7 from Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization
2025 · Sontoria D. King, Swathi Veliginti, et al.
Supplementary Table S3 from Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization
2025 · Sontoria D. King, Swathi Veliginti, et al.
Supplementary Table S10 from Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization
2025 · Sontoria D. King, Swathi Veliginti, et al.
Supplementary Figure S1 from Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization
2025 · Sontoria D. King, Swathi Veliginti, et al.
Supplementary Table S1 from Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization
2025 · Sontoria D. King, Swathi Veliginti, et al.
Supplementary Table S9 from Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization
2025 · Sontoria D. King, Swathi Veliginti, et al.
Supplementary Table S5 from Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization
2025 · Sontoria D. King, Swathi Veliginti, et al.
Supplementary Table S2 from Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization
2025 · Sontoria D. King, Swathi Veliginti, et al.
Supplementary Figure S2 from Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization
2025 · Sontoria D. King, Swathi Veliginti, et al.
Supplementary Table S4 from Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization
2025 · Sontoria D. King, Swathi Veliginti, et al.
Supplementary Table S8 from Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization
2025 · Sontoria D. King, Swathi Veliginti, et al.
Supplementary Table S6 from Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization
2025 · Sontoria D. King, Swathi Veliginti, et al.
Steatotic liver disease interacts with a polygenic risk score for triglyceride clearance to impact the risk of hypertriglyceridaemia: The Maastricht Study
2025 · Zhewen Ren, Anke Wesselius, et al. · Diabetologia
PDF
Socioeconomic determinants and cardiometabolic consequences of non-alcoholic fatty liver disease
2025 · Zhewen Ren
Supplementary Table S9 from Genetic susceptibility to nonalcoholic fatty liver disease and risk for pancreatic cancer: Mendelian randomization
2024 · Sontoria D. King, Swathi Veliginti, et al.
Supplementary Table S7 from Genetic susceptibility to nonalcoholic fatty liver disease and risk for pancreatic cancer: Mendelian randomization
2024 · Sontoria D. King, Swathi Veliginti, et al.
Supplementary Table S8 from Genetic susceptibility to nonalcoholic fatty liver disease and risk for pancreatic cancer: Mendelian randomization
2024 · Sontoria D. King, Swathi Veliginti, et al.
Supplementary Table S6 from Genetic susceptibility to nonalcoholic fatty liver disease and risk for pancreatic cancer: Mendelian randomization
2024 · Sontoria D. King, Swathi Veliginti, et al.
Works count: 100
Citation count: 182
H-index: 6
I10-index: 4
Year
Topic
Type